Monograph
J07BK02 - Zoster, Live Attenuated |
Propably not porphyrinogenic |
PNP |
Rationale
Based on its pharmacokinetics properties the zoster vaccine has no conceivable porphyrinogenic effects.
Chemical description
Varicella-zoster virus live, attenuated. Produced in human diploid cells
Therapeutic characteristics
The zoster-vaccine is indicated for prevention of herpes zoster and herpes zoster-related post-herpetic neuralgia (PHN), in individuals over 50 years.
The vaccine can be injected subcutaneously or intramuscularly as a single dose.
Metabolism and pharmacokinetics
The zoster vaccine is not metabolized by the cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Zostavax. (Last edition:
February. 2016). |
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Poland
Luxembourg
Iceland
Finland
Latvia© NAPOS 2024